Pacific Edge Tests Processed in Fiscal Q2 Fall 2%; Shares Down 4%

MT Newswires Live10-09

Cancer diagnostics company Pacific Edge (NZE:PEB, ASX:PEB) said tests processed at its laboratories in the three months to the end of September were 2% lower than the prior quarter at 7,045, according to a Wednesday filing with the Australian and New Zealand bourses.

Asia Pacific volumes rose 6.2% to 1,363 tests from 1,283 in fiscal Q1, reflecting increased volumes in New Zealand and small growth from Australia and Asian distributors, the filing stated.

Group test volumes for the half year fell 22% to 14,233 from 18,240 in the first half of fiscal 2024, according to the filing.

Pacific Edge shares fell past 4% in recent Wednesday trade in New Zealand.

Price (AUD): $0.16, Change: $-0.0070, Percent Change: -4.32%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474287218?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-09 06:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474287218","market":"sg","top_or_hot":-1,"title":"Pacific Edge Tests Processed in Fiscal Q2 Fall 2%; Shares Down 4%","media":"MT Newswires Live","content":"<html><body><p> Cancer diagnostics company Pacific Edge (NZE:PEB, ASX:PEB) said tests processed at its laboratories in the three months to the end of September were 2% lower than the prior quarter at 7,045, according to a Wednesday filing with the Australian and New Zealand bourses.</p><p>Asia Pacific volumes rose 6.2% to 1,363 tests from 1,283 in fiscal Q1, reflecting increased volumes in New Zealand and small growth from Australia and Asian distributors, the filing stated.</p><p>Group test volumes for the half year fell 22% to 14,233 from 18,240 in the first half of fiscal 2024, according to the filing.</p><p>Pacific Edge shares fell past 4% in recent Wednesday trade in New Zealand.</p><p>Price (AUD): $0.16, Change: $-0.0070, Percent Change: -4.32%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacific Edge Tests Processed in Fiscal Q2 Fall 2%; Shares Down 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacific Edge Tests Processed in Fiscal Q2 Fall 2%; Shares Down 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-09 06:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cancer diagnostics company Pacific Edge (NZE:PEB, ASX:PEB) said tests processed at its laboratories in the three months to the end of September were 2% lower than the prior quarter at 7,045, according...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XJO.AU","symbol_name":"标普/澳交所 200指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2474287218","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474287218","pubTimestamp":1728426553,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cancer diagnostics company Pacific Edge  said tests processed at its laboratories in the three months to the end of September were 2% lower than the prior quarter at 7,045, according to a Wednesday filing with the Australian and New Zealand bourses.Asia Pacific volumes rose 6.2% to 1,363 tests from 1,283 in fiscal Q1, reflecting increased volumes in New Zealand and small growth from Australia and Asian distributors, the filing stated.Group test volumes for the half year fell 22% to 14,233 from 18,240 in the first half of fiscal 2024, according to the filing.Pacific Edge shares fell past 4% in recent Wednesday trade in New Zealand.Price : $0.16, Change: $-0.0070, Percent Change: -4.32%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XJO.AU":"标普/澳交所 200指数","BK7067":"生物科技","NZ20C.NZ":"S&P/NZX 20","BK4125":"广播","XKO.AU":"标普/澳交所 300指数","NZ50G.NZ":"S&P/NZX 50","PEB.AU":"PACIFIC EDGE LTD","AUD":"Audacy Inc.","XAO.AU":"标普/澳交所 普通股指数","T10G.NZ":"S&P/NZX 10"},"translate_title":"第二财季处理的Pacific Edge测试下降2%；股价下跌4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"PEB.AU":0.9,"XAO.AU":0.82,"XJO.AU":0.82,"XKO.AU":0.82,"NZ20C.NZ":0.62,"NZ50G.NZ":0.62,"T10G.NZ":0.62},"content_text":"Cancer diagnostics company Pacific Edge (NZE:PEB, ASX:PEB) said tests processed at its laboratories in the three months to the end of September were 2% lower than the prior quarter at 7,045, according to a Wednesday filing with the Australian and New Zealand bourses.Asia Pacific volumes rose 6.2% to 1,363 tests from 1,283 in fiscal Q1, reflecting increased volumes in New Zealand and small growth from Australia and Asian distributors, the filing stated.Group test volumes for the half year fell 22% to 14,233 from 18,240 in the first half of fiscal 2024, according to the filing.Pacific Edge shares fell past 4% in recent Wednesday trade in New Zealand.Price (AUD): $0.16, Change: $-0.0070, Percent Change: -4.32%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474287218"}